David Z.I. Cherney

25.8k total citations · 16 hit papers
331 papers, 14.8k citations indexed

About

David Z.I. Cherney is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Surgery. According to data from OpenAlex, David Z.I. Cherney has authored 331 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 230 papers in Endocrinology, Diabetes and Metabolism, 106 papers in Nephrology and 99 papers in Surgery. Recurrent topics in David Z.I. Cherney's work include Diabetes Treatment and Management (181 papers), Chronic Kidney Disease and Diabetes (82 papers) and Pancreatic function and diabetes (81 papers). David Z.I. Cherney is often cited by papers focused on Diabetes Treatment and Management (181 papers), Chronic Kidney Disease and Diabetes (82 papers) and Pancreatic function and diabetes (81 papers). David Z.I. Cherney collaborates with scholars based in Canada, United States and Netherlands. David Z.I. Cherney's co-authors include Bruce A. Perkins, Hiddo J.L. Heerspink, Yuliya Lytvyn, Petter Bjornstad, Vesta Lai, Maximilian von Eynatten, Christopher P. Cannon, Mansoor Husain, Darren K. McGuire and David Fitchett and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

David Z.I. Cherney

314 papers receiving 14.6k citations

Hit Papers

Cardiovascular Outcomes with Ertugliflo... 2013 2026 2017 2021 2020 2013 2016 2020 2020 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
    2020 1.0k citations Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine profile →
  2. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
    2013 976 citations David Z.I. Cherney, Bruce A. Perkins et al. Circulation profile →
  3. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus
    2016 946 citations Hiddo J.L. Heerspink, Bruce A. Perkins et al. Circulation profile →
  4. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
    2020 789 citations Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine profile →
  5. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
    2020 708 citations Darren K. McGuire, Weichung Shih et al. profile →
  6. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
    2014 380 citations David Z.I. Cherney, Bruce A. Perkins et al. profile →
  7. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
    2017 332 citations Yuliya Lytvyn, Petter Bjornstad et al. Circulation profile →
  8. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
    2017 287 citations David Z.I. Cherney, Silvio E. Inzucchi et al. profile →
  9. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    2018 265 citations Hiddo J.L. Heerspink, Mikhail Kosiborod et al. profile →
  10. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
    2018 247 citations David Z.I. Cherney et al. Diabetologia profile →
  11. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
    2018 244 citations Julio Rosenstock, David Z.I. Cherney et al. Diabetes Care profile →
  12. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
    2022 178 citations Hiddo J.L. Heerspink, Katherine R. Tuttle et al. profile →
  13. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
    2022 135 citations Kevin Yau, David Z.I. Cherney et al. profile →
  14. Obesity and the kidney: mechanistic links and therapeutic advances
    2024 47 citations Kevin Yau, David Z.I. Cherney et al. profile →
  15. Combination therapy for kidney disease in people with diabetes mellitus
    2024 45 citations Daniël H. van Raalte, Petter Bjornstad et al. profile →
  16. Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Clinical Trials
    2025 20 citations Katherine R. Tuttle, David Z.I. Cherney et al. Diabetes Care profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Z.I. Cherney Canada 55 10.7k 4.9k 3.8k 3.6k 2.9k 331 14.8k
Michaela Mattheus Germany 28 11.5k 1.1× 4.9k 1.0× 1.8k 0.5× 4.6k 1.2× 2.9k 1.0× 84 13.7k
Odd Erik Johansen United States 35 14.8k 1.4× 6.3k 1.3× 2.1k 0.5× 5.8k 1.6× 3.8k 1.3× 123 17.8k
David Fitchett Canada 47 12.8k 1.2× 6.8k 1.4× 1.8k 0.5× 5.3k 1.4× 5.9k 2.0× 200 18.7k
Hans J. Woerle Germany 49 11.4k 1.1× 5.5k 1.1× 1.8k 0.5× 5.1k 1.4× 1.2k 0.4× 89 13.3k
Maximilian von Eynatten Germany 44 8.2k 0.8× 3.5k 0.7× 2.0k 0.5× 3.2k 0.9× 1.6k 0.5× 115 11.0k
Ofri Mosenzon Israel 40 13.3k 1.2× 4.8k 1.0× 1.1k 0.3× 5.4k 1.5× 3.5k 1.2× 142 15.9k
Uli C. Broedl Germany 55 18.6k 1.7× 9.2k 1.9× 2.5k 0.7× 8.3k 2.3× 4.2k 1.5× 118 23.1k
C. David Sjöström Sweden 44 6.2k 0.6× 5.6k 1.1× 2.0k 0.5× 2.2k 0.6× 1.6k 0.5× 116 12.1k
Greg Fulcher Australia 32 7.8k 0.7× 3.4k 0.7× 1.1k 0.3× 2.9k 0.8× 1.8k 0.6× 65 9.5k
Mehul Desai United States 30 7.8k 0.7× 3.4k 0.7× 968 0.3× 3.3k 0.9× 2.0k 0.7× 49 9.5k

Countries citing papers authored by David Z.I. Cherney

Since Specialization
Citations

This map shows the geographic impact of David Z.I. Cherney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Z.I. Cherney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Z.I. Cherney more than expected).

Fields of papers citing papers by David Z.I. Cherney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Z.I. Cherney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Z.I. Cherney. The network helps show where David Z.I. Cherney may publish in the future.

Co-authorship network of co-authors of David Z.I. Cherney

This figure shows the co-authorship network connecting the top 25 collaborators of David Z.I. Cherney. A scholar is included among the top collaborators of David Z.I. Cherney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Z.I. Cherney. David Z.I. Cherney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ray, Joel G., Kevin Yau, Nivethika Jeyakumar, et al.. (2025). SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors. JAMA Internal Medicine. 185(7). 827–827. 2 indexed citations
2.
Schuett, Katharina, David Z.I. Cherney, Joachim Jankowski, et al.. (2025). Cardiovascular disease in chronic kidney disease. European Heart Journal. 46(23). 2148–2160. 8 indexed citations
3.
Heerspink, Hiddo J.L., Rajiv Agarwal, Antonio J. Amor, et al.. (2025). Comparing CKD populations with T1D and T2D: a perspective based on the FINE-ONE and FIDELITY populations. Nephrology Dialysis Transplantation. 41(3). 556–565. 1 indexed citations
4.
Sridhar, Vikas S., Ayodele Odutayo, Thomas Danne, et al.. (2024). Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD. Journal of the American Society of Nephrology. 36(5). 890–900. 5 indexed citations
5.
Nardone, Massimo, Kevin Yau, Ayodele Odutayo, et al.. (2024). Upcoming drug targets for kidney protective effects in chronic kidney disease. Nephrology Dialysis Transplantation. 40(Supplement_1). i47–i58. 2 indexed citations
6.
Siddiqi, Tariq Jamal, David Z.I. Cherney, Tazeen H. Jafar, et al.. (2024). Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions. Journal of the American Society of Nephrology. 36(2). 242–255. 4 indexed citations
7.
Badrov, Mark B., Catherine F. Notarius, Massimo Nardone, et al.. (2024). Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction. Circulation Heart Failure. 18(1). e011962–e011962.
8.
Sridhar, Vikas S., Manuel López Mendoza, David Z.I. Cherney, et al.. (2024). Kidney hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in diabetes: physiology and clinical implications. Clinical Kidney Journal. 18(1). sfae370–sfae370. 2 indexed citations
9.
Heerspink, Hiddo J.L., Melanie J. Davies, Dror Dicker, et al.. (2023). Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials. Diabetes Care. 46(4). 801–810. 63 indexed citations
10.
Sridhar, Vikas S., Christine P. Limonte, Per‐Henrik Groop, et al.. (2023). Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes. Diabetologia. 67(1). 3–18. 17 indexed citations
11.
Sridhar, Vikas S., Brendon L. Neuen, Robert A. Fletcher, et al.. (2023). Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials. Diabetes Obesity and Metabolism. 25(8). 2331–2339. 5 indexed citations
12.
Lytvyn, Yuliya, Karen Kimura, Nuala Peter, et al.. (2022). Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition. Circulation. 146(6). 450–462. 41 indexed citations
13.
Tuttle, Katherine R., Leslie P. Wong, Wendy L. St. Peter, et al.. (2022). Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology. 17(7). 1092–1103. 42 indexed citations
14.
Weisman, Alanna, George Tomlinson, Lorraine L. Lipscombe, et al.. (2021). Allopurinol and Renal Outcomes in Adults With and Without Type 2 Diabetes: A Retrospective, Population-Based Cohort Study and Propensity Score Analysis. Canadian Journal of Diabetes. 45(7). 641–649.e4. 4 indexed citations
15.
Cherney, David Z.I., Dick de Zeeuw, Hiddo J.L. Heerspink, et al.. (2021). Phase Ib Study of the Soluble Guanylate Cyclase Activator BI 685509 in Patients with Diabetic Kidney Disease. Journal of the American Society of Nephrology. 32(10S). 264–264. 1 indexed citations
16.
Brosius, Frank C., David Z.I. Cherney, Patrick O. Gee, et al.. (2021). Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology. 16(10). 1590–1600. 14 indexed citations
17.
Bhatt, Deepak L., Michael Szarek, Bertram Pitt, et al.. (2020). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 384(2). 129–139. 789 indexed citations breakdown →
18.
Cosentino, Francesco, Christopher P. Cannon, David Z.I. Cherney, et al.. (2020). Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation. 142(23). 2205–2215. 175 indexed citations
19.
Cherney, David Z.I., et al.. (2018). Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease. American Journal of Physiology-Renal Physiology. 315(5). F1406–F1415. 19 indexed citations
20.
Cherney, David Z.I., Bruce A. Perkins, Nima Soleymanlou, et al.. (2013). Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus. Circulation. 129(5). 587–597. 976 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michaela Mattheus Breakdown of academic impact, for papers by Odd Erik Johansen Breakdown of academic impact, for papers by David Fitchett Breakdown of academic impact, for papers by Hans J. Woerle Breakdown of academic impact, for papers by Maximilian von Eynatten Breakdown of academic impact, for papers by Ofri Mosenzon Breakdown of academic impact, for papers by Uli C. Broedl Breakdown of academic impact, for papers by C. David Sjöström Breakdown of academic impact, for papers by Greg Fulcher Breakdown of academic impact, for papers by Mehul Desai
Rankless by CCL
2026